Imatinib: novel treatment of immune-mediated kidney injury.
暂无分享,去创建一个
[1] W. Couser. Basic and translational concepts of immune-mediated glomerular diseases. , 2012, Journal of the American Society of Nephrology : JASN.
[2] R. Nagai,et al. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases , 2012, Modern rheumatology.
[3] V. Kelley,et al. Distinct roles of CSF-1 isoforms in lupus nephritis. , 2011, Journal of the American Society of Nephrology : JASN.
[4] P. Koskinen,et al. Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] T. Akizawa,et al. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.
[6] C. Chatziantoniou,et al. Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. , 2011, The American journal of pathology.
[7] J. Gordon,et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial , 2011, Annals of the rheumatic diseases.
[8] E. Neilson,et al. Mechanisms of tubulointerstitial fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.
[9] A. Marini,et al. Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. , 2010, Leukemia research.
[10] A. Zimmermann,et al. Imatinib mesylate induces clinical remission in rheumatoid arthritis. , 2010, Joint, bone, spine : revue du rhumatisme.
[11] D. Schroeder,et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. , 2010, American journal of respiratory and critical care medicine.
[12] M. Mack. Podocyte antigens, dendritic cells and T cells contribute to renal injury in newly developed mouse models of glomerulonephritis. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] Hans-Peter Lipp,et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. , 2009, Current drug metabolism.
[14] D. Nikolic-Paterson,et al. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice , 2009, Diabetologia.
[15] M. Kawaguchi,et al. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. , 2009, Kidney international.
[16] S. Goff,et al. c-Abl-deficient mice exhibit reduced numbers of peritoneal B-1 cells and defects in BCR-induced B cell activation. , 2009, International immunology.
[17] E. Buchdunger,et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. , 2008, European journal of pharmacology.
[18] J. Kay,et al. Imatinib mesylate treatment of nephrogenic systemic fibrosis. , 2008, Arthritis and rheumatism.
[19] R. Marasca,et al. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor , 2008, Haematologica.
[20] M. Koury,et al. Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. , 2007, Clinical nephrology.
[21] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[22] J. Rintala,et al. Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation. , 2006, Transplantation proceedings.
[23] W. Vogel,et al. Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. , 2006, Journal of the American Society of Nephrology : JASN.
[24] F. Magro,et al. Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. , 2006, Inflammatory bowel diseases.
[25] F. M. Thomas,et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. , 2006, The Journal of clinical investigation.
[26] G. Remuzzi,et al. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. , 2006, Kidney international.
[27] H. Hirakata,et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. , 2005, Arthritis and rheumatism.
[28] I. Shiraishi,et al. Adoptive transfer of macrophages ameliorates renal fibrosis in mice. , 2005, Biochemical and biophysical research communications.
[29] A. B. Lyons,et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. , 2005, Blood.
[30] D. Douek,et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. , 2005, Blood.
[31] M. Cooper,et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. , 2005, Journal of the American Society of Nephrology : JASN.
[32] N. Donato,et al. Imatinib mesylate (Gleevec, STI-571) suppresses cytokine production by normal T-cells activated through T-cell receptor (TCR) signaling , 2005 .
[33] A. B. Lyons,et al. Imatinib inhibits the functional capacity of cultured human monocytes , 2005, Immunology and cell biology.
[34] E. Leof,et al. The FASEB Journal • Research Communication Imatinib mesylate blocks a non-Smad TGF- � pathway and reduces renal fibrogenesis in vivo , 2022 .
[35] J. Melo,et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro , 2004, Leukemia.
[36] K. Manova,et al. Critical Role for Kit-mediated Src Kinase But Not PI 3-Kinase Signaling in Pro T and Pro B Cell Development , 2004, The Journal of experimental medicine.
[37] L. Zitvogel,et al. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. , 2004, Blood.
[38] T. Brümmendorf,et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. , 2004, Blood.
[39] E. Taskinen,et al. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy , 2003, Transplantation.
[40] G. Superti-Furga,et al. Phosphorylation of Bruton's tyrosine kinase by c-Abl. , 2002, Biochemical and biophysical research communications.
[41] S. Klahr,et al. Obstructive nephropathy and renal fibrosis. , 2002, American journal of physiology. Renal physiology.
[42] R. Atkins,et al. Macrophage accumulation at a site of renal inflammation is dependent on the M‐CSF/c‐fms pathway , 2002, Journal of leukocyte biology.
[43] M. Gassmann,et al. Viable c-Kit(W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. , 2002, Immunity.
[44] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[45] R. Atkins,et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. , 2001, Kidney international.
[46] P. Zipfel,et al. The c-Abl Tyrosine Kinase Is Regulated Downstream of the B Cell Antigen Receptor and Interacts with CD191 , 2000, The Journal of Immunology.
[47] D. Robinson,et al. The protein tyrosine kinase family of the human genome , 2000, Oncogene.
[48] Eric O Long,et al. Essential role of LAT in T cell development. , 1999, Immunity.
[49] M. Fujimoto,et al. CD19 regulates B lymphocyte responses to transmembrane signals. , 1998, Seminars in immunology.
[50] M. Carroll,et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.
[51] F. Alt,et al. Abnormal peripheral lymphocyte function in c-abl mutant mice. , 1996, Cellular immunology.
[52] P. Tipping,et al. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[53] S. Goff,et al. Mice homozygous for the abl m1 mutation show poor viability and depletion of selected B and T cell populations , 1991, Cell.
[54] P. Tipping,et al. Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis. , 1989, Kidney international.
[55] A. Fogo,et al. Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[56] K. Mace,et al. Progenitor Cells , 2012, Methods in Molecular Biology.
[57] D. Harris,et al. Macrophages in renal disease. , 2011, Journal of the American Society of Nephrology : JASN.
[58] E. Leof,et al. Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. , 2010, American journal of physiology. Renal physiology.
[59] S. Ziegler,et al. Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.
[60] A. Azzará,et al. Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. , 2008, Leukemia research.
[61] C. Alpers,et al. A new look at platelet-derived growth factor in renal disease. , 2008, Journal of the American Society of Nephrology : JASN.
[62] H. Kantarjian,et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia , 2005, Leukemia.
[63] Jonathan T. Pribila,et al. Signal transduction events regulating integrin function and T cell migration , 2003, Immunologic research.
[64] E. Arranz,et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. , 2003, Haematologica.
[65] K. Matsumoto. Production of interleukin-1 in macrophage cultures from rats with nephrotoxic serum nephritis. , 1988, International archives of allergy and applied immunology.
[66] C. Alpers,et al. Renin-angiotensin System Blockade Is Renoprotective in Immune Complex–mediated Glomerulonephritis , 2022 .